RCS - Ondine Biomedical - Steriwave Now Protecting Patients with Cancer

Ondine BiomedicalAnnouncement

23/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250923:nRSW3369Aa&default-theme=true

RNS Number : 3369A  Ondine Biomedical Inc.  23 September 2025

23 September 2025

 

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 

Steriwave Now Protecting Patients with Cancer

The Mater Hospital, North Sydney, Adopts Steriwave to Combat AMR in Cancer
Care

·   Antimicrobial resistance (AMR) is driving higher mortality, morbidity,
and healthcare costs for patients with cancer.

·    Hospitalized patients with cancer face up to twice the risk of
antibiotic-resistant infections.

·   AMR pathogens are up to three times as prevalent in outpatients with
cancer compared with patients without cancer.

Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering
light-activated, non-antibiotic infection prevention therapies, announces that
The Mater Hospital, North Sydney, has introduced Steriwave(®) nasal
photodisinfection into its oncology program to help combat the growing threat
of antimicrobial resistance (AMR) in cancer care. Mounting evidence shows
people with cancer face significantly higher risks from drug-resistant
infections-a challenge the hospital is determined to address head-on.

Patients with cancer, particularly those undergoing chemotherapy, radiation,
stem cell transplants or surgery, are highly vulnerable to infection due to
weakened immune systems and frequent healthcare exposure. These risks are
magnified by the rise of antibiotic-resistant bacteria.

Recent studies underscore these risks:

·    Hospitalized patients with cancer face 1.5 to 2 times higher rates
of AMR infections than other inpatients (Gupta et al., Cancer Medicine, 2024).

·     Outpatients with cancer experience up to 3 times higher rates of
AMR pathogens, such as VRE (vancomycin-resistant enterococci), ESBL-producing
Enterobacterales, and carbapenem-resistant Pseudomonas (Gupta et al., Lancet
Oncology, 2025).

·     In patients with hematologic malignancies, AMR infections occur in
up to 35% of cases and are closely linked with increased mortality (Sallah et
al., Lancet Oncology, 2025).

Steriwave is a non-invasive and painless treatment that uses a proprietary
light-activated photosensitive agent to destroy harmful bacteria, viruses, and
fungi-including antibiotic-resistant strains-in the nasal passages. The
procedure takes five minutes and, unlike antibiotics, is effective immediately
and allows the normal nasal microbiome to recover quickly, without fostering
antimicrobial resistance.

Carolyn Cross, CEO of Ondine Biomedical:

"We are pleased to collaborate with Professor Boyle and the Mater team to
bring Steriwave to people battling cancer. This marks an important step in
expanding Steriwave's role beyond surgical and ICU settings into broader
cancer care, where the need is increasingly urgent."

A Cost-Effective and Life-Saving Strategy

The challenge:

·  Resistant infections drive up costs through prolonged hospital stays,
expensive last-line antibiotics, and added staffing requirements.

·   AMR increases morbidity and mortality by delaying or disrupting
life-saving treatments like chemotherapy or transplants.

·      Health equity gaps widen in settings with limited access to
advanced antibiotics and diagnostics (Shropshire & Shelburne, Lancet
Oncology, 2025).

How Steriwave helps:

·   Steriwave reduces infection rates, shortening hospital stays and
lowering reliance on costly drugs.

·    Preventing resistant infections allows patients to stay on schedule
with critical cancer therapies.

·    As a non-antibiotic, low-cost intervention, Steriwave supports more
equitable access to infection prevention worldwide.

As AMR continues to rise globally, incorporating preventive innovations like
Steriwave into oncology care can help protect people with cancer, sustain
life-saving treatments, and ease growing pressures on healthcare systems.

 

About The Mater Hospital, North Sydney

The Mater Hospital, North Sydney, part of St Vincent's Health Australia, is a
leading not-for-profit hospital providing compassionate, high-quality care
across oncology, surgery, palliative care, and other specialties. The
hospital's Patricia Ritchie Centre for Cancer Care and Research is
internationally recognized for excellence in oncology and commitment to
innovation that improves patient outcomes.

St Vincent's operates 10 private hospitals across New South Wales (three),
Victoria (four), and Queensland (three), serving both metropolitan and
regional communities. St Vincent's private hospitals have been ranked first
for five years in a row by Medibank's overnight patient customers in all 10
categories surveyed, reflecting its consistently high standard of patient care
and experience.

 

Enquiries:

 Ondine Biomedical Inc.                                            www.ondinebio.com
 Carolyn Cross, CEO                                                +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Joint Financial Adviser)
 James Harris, Richard Johnson                                     +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Advisor)
 James Steel, Dr. Chris Golden                                     +44 (0)20 7418 8900

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                                  +44 (0)77 1000 5910

 

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved
for nasal decolonisation in Canada, Australia, Mexico and several other
countries under the name Steriwave(®). In the US, it has been granted
Qualified Infectious Disease Product designation and Fast Track status by the
FDA and is currently undergoing clinical trials for regulatory approval.
Products beyond nasal photodisinfection include therapies for a variety of
medical indications such as chronic sinusitis, ventilator-associated
pneumonia, burns and other indications.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPKBBPKBKBACB